BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant,  Merck  Sharp  &  Dohme  Limited,  submitted  on  10  October  2000  an  application  for 
Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) 
for Caspofungin MSD, through the centralised procedure. After agreement by the CPMP on 25  May 
2000, this medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 
2309/93 of 22 July 1993, as amended. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur: 
Pharm. De Greef 
 Co-Rapporteur: Dr. Tomas Salmonson 
Scientific Advice: 
The  applicant  received  Scientific  Advice  from  the  CPMP  on  16  December  1999.  The  Scientific 
Advice pertained to Part IV  (clinical development) of the dossier.  
Licensing status: 
Caspofungin has been given a Marketing Authorisation in the United States on 29 January 2001. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The procedure started on 31 October 2000. 
The Rapporteur's first Assessment Report was circulated to all CPMP members on 16 January 
2001. The Co-Rapporteur's first Assessment Report was circulated to all CPMP members on 15 
January 2001. 
During the meeting on 27 February-1 March 2001, the CPMP agreed on the consolidated List of 
Questions to be sent to the applicant. The final consolidated List of Questions  was sent to the 
applicant on 1 March 2001. 
The applicant submitted the responses to the CPMP consolidated List of Questions on 22 March 
2001. 
The draft summary report of the inspection carried  out between 9-13 April 2001 at one of the 
manufacturing sites of the finished medicinal product was issued on 25 June 2001. 
The  Rapporteur  and  Co-rapporteur  circulated  the  joint  Assessment  Report  on  the  applicant’s 
responses to the consolidated List of Questions to all CPMP members on 7 May 2001. 
An  updated joint Rapporteur/Co-Rapporteur  Assessment Report  on the responses provided  by 
the applicant, was circulated to all CPMP members on 21 May 2001. 
During the CPMP meeting 29-31 May 2001, outstanding issues were addressed by the applicant 
during  a  hearing  before  the  CPMP.  The  CPMP  agreed  on  a  list  of  outstanding  issues  to  be 
addressed in writing by the applicant. This list was sent to the applicant on 31 May 2001.  
The applicant submitted the responses to the list of outstanding issues on 25 June 2001. 
The  Rapporteur  and  Co-Rapporteur  circulated  the  joint  Assessment  Report  on  the  applicant’s 
responses to all CPMP members on 11 July 2001. 
The applicant provided an undertaking letter of the specific obligations and follow-up measures 
to be fulfilled post authorisation on 25 July 2001. 
During the meeting on 24-26 July 2001 the CPMP, in the light of the overall data submitted and 
the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to Caspofungin MSD on 26 July 2001. 
The EMEA forwarded the opinion to the European Commission who issued on 24 October 2001 
the respective Decision for granting a Marketing Authorisation under exceptional circumstances 
to Caspofungin MSD. 
  1/1 

EMEA 2004 
 
 
 
 
 
 
 
 
 
 
 
 
